

## Corporate Profile

Meridian is a fully integrated life science company that develops, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company's shares are traded through NASDAQ's Global Select Market, symbol VIVO. Meridian's website address is [www.meridianbioscience.com](http://www.meridianbioscience.com).

## Primary IR Contact

Melissa Lueke  
Executive Vice President  
Chief Financial Officer  
Meridian Bioscience, Inc.

## Stock Performance

VIVO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$15.25
Change (%)	▼ 0.25 (1.61%)
Volume	79,512
52 Week Low	\$10.75
Market Cap	\$654,143,509
Rolling EPS	0.70
PE Ratio	22.0817
Shares Outstanding	42,202,807

Data as of 07/21/17 12:26 p.m. ET



## Recent Press Releases

7/20/2017

Meridian Announces Wholly Foreign Owned Enterprise (WFOE) Office in Beijing, China

7/13/2017

Meridian Bioscience Comments on Recent FDA Press Statement

6/30/2017

Meridian Bioscience Comments on Recent FDA Matters Related to Magellan Diagnostics

6/28/2017

Meridian Bioscience, Inc. Expects to Report Third Quarter Fiscal 2017 Operating Results on Thursday, July 27, 2017

6/6/2017

Meridian Bioscience Comments on Recent FDA Posting Related to Magellan Diagnostics


## Upcoming Events

There are currently no events scheduled.

## Recent SEC Filings

Filing Date	Form	Description
05/23/17	SD	Specialized Disclosure Report
05/23/17	4	Statement of changes in beneficial ownership of securities
05/10/17	8-K	Report of unscheduled material events or corporate event
05/10/17	10-Q	Quarterly report which provides a continuing view of a company's financial position

## Analyst Estimates / Ratings



## Management

### John A. Kraeutler

Chairman of the Board, Chief Executive Officer

### Lawrence J. Baldini

Executive Vice President and President, Global Operations

### Marco Calzavara

President, Meridian Bioscience Europe

### Richard L. Eberly

Executive Vice President, President and Chief Commercial Officer

### Slava A. Elagin

Executive Vice President, Research and Product Development

### Melissa A. Lueke

Executive Vice President, Chief Financial Officer

### Susan D. Rolih

Executive Vice President Regulatory Affairs and Quality Assurance

### Lourdes G. Weltzien

Vice President & General Manager, President Asia Pacific Markets

### Amy M. Winslow

Executive Vice President, President and CEO Magellan Diagnostics

## EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Jun 17	0.17	0.17	0.17
QTR	Sep 17	0.15	0.15	0.15
QTR	Dec 17	0.16	0.16	0.16
QTR	Mar 18	0.21	0.21	0.19
FY	Sep 17	0.68	0.68	0.66
FY	Sep 18	0.70	0.70	0.68

## Board of Directors

### John A. Kraeutler

Chairman of the Board, Chief Executive Officer

### James M. Anderson

Retired President and Chief Executive Officer Cincinnati Children's Hospital Medical Center

### David C. Phillips

Co-founder Cincinnati Works, Inc

### Dwight (Dee) E. Ellingwood

President, D.E.E. Strategy Consulting, LLC

### John C. McIlwraith

Co-founder Allos Ventures

### Catherine A. Sazdanoff

Chief Business Officer of Strata Oncology, Inc

## Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	238	546.60	91.7	38,704,086
Mutual Fund	278	311.25	49.6	20,928,014
Insider *	14	16.44	2.4	1,021,169

\*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
Brown Capital Management, LLC	5,683,095	13.5	-8,536	03/31/17
BlackRock Institutional Trust Company, N.A.	4,780,199	11.3	306,979	03/31/17
The Vanguard Group, Inc.	3,684,505	8.7	70,081	03/31/17
Renaissance Technologies LLC	1,988,276	4.7	115,076	03/31/17
Dimensional Fund Advisors, L.P.	1,427,828	3.4	29,755	03/31/17
State Street Global Advisors (US)	1,243,847	3.0	163,770	03/31/17
M & G Investment Management Ltd.	1,174,500	2.8	156,200	03/31/17
Norges Bank Investment Management (NBIM)	1,136,022	2.7	118,216	12/31/16
New York State Common Retirement Fund	1,059,988	2.5	1	03/31/17
Boston Trust & Investment Management Company	709,363	1.7	-226,227	06/30/17

Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Minimum 20 minutes delayed